Financing channel feed

Lo­cus pulls in a mod­est Se­ries B as it at­tempts to em­u­late on­col­o­gy's pre­ci­sion med­i­cine mod­el in an­tibac­te­ri­als

3 years ago
Startups

Re­gen­eron-backed on­colyt­ic virus start­up scores mod­est Se­ries B ex­ten­sion

3 years ago

Fol­low­ing po­ten­tial bil­lion-dol­lar J&J deal, RNA pro­cess­ing biotech Remix re­turns with fresh fi­nanc­ing

3 years ago

Pfiz­er-part­nered Zen­tal­is woos new CEO, cob­bles to­geth­er $200M

3 years ago
People

An­oth­er pri­vate eq­ui­ty gi­ant makes a big move in­to biotech as Apol­lo ex­e­cutes €1B play — while life sci stocks shriv­el

3 years ago

Star­na Ther­a­peu­tics emerges with fi­nanc­ing for mR­NA vac­cine and ther­a­pies

3 years ago
Startups
China

With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

3 years ago
Startups
Cell/Gene Tx

With 30-year in­dus­try chops, Pamela Con­ley launch­es a pro­tein ther­a­peu­tics biotech for au­toim­mune dis­eases

4 years ago
Startups

Up­dat­ed: A GPCR start­up out of France and Cana­da scores its Se­ries A af­ter 14 years of wheel­ing and deal­ing

4 years ago

Can On­co­Host's PROphet pre­dict host re­sponse to can­cer treat­ments? In­vestors are wait­ing to find out

4 years ago
Diagnostics

Work­ing like a ma­chine dur­ing the pan­dem­ic, MO­MA taps in­vestors to bankroll its 'mol­e­c­u­lar ma­chi­nes'

4 years ago
Startups

Ex­clu­sive: As­pen Neu­ro­science col­lects large Se­ries B to com­pete against Bay­er's Parkin­son's cell ther­a­py

4 years ago
Startups
Cell/Gene Tx

De­fy­ing biotech bears, Sanofi man­u­fac­tur­ing spin­off surges on Paris de­but

4 years ago
Pharma

BeiGene CEO John Oyler steps up to the Big Phar­ma league with $16M in comp as shares sour

4 years ago
Pharma

Big Phar­ma is rich. So much so, their cof­fers could buy more than 600 biotechs

4 years ago
Deals
Pharma

Bear mar­ket slows Pep­Gen's roll, caus­ing DMD-fo­cused biotech to price be­low range

4 years ago

In­ter­cept sells ex-US rights to PBC drug as it gears up for a sec­ond-chance shot at NASH

4 years ago
Deals
Pharma

DCT start­up look­ing to forge bet­ter com­mu­ni­ty re­la­tion­ships nets a mod­est Se­ries B

4 years ago
Startups

Feel­ing the pain of a bear mar­ket, Macro­Gen­ics plans to start a PhII/III by year's end — once they raise the cash

4 years ago

Sleep ap­nea biotech breathes easy with $62.5M fi­nanc­ing ahead of PhI­II tri­als for lead oral drug

4 years ago

How do you pack 20 years of ADC learn­ings in­to one com­pa­ny? Tubu­lis has $63M more to an­swer that

4 years ago
Startups

Af­ter 45 in­vest­ments in two years, Catalio reels in more funds to back 30 ad­di­tion­al com­pa­nies

4 years ago
Startups

5AM, Avid­i­ty, Fi­deli­ty lead $100M in­fu­sion in­to next-gen, tar­get­ed com­ple­ment ap­proach

4 years ago
Startups

An­oth­er pub­lic biotech hops on the tri­al-win-to-stock-sale train, net­ting a nine-fig­ure raise

4 years ago
First page Previous page 54555657585960 Next page Last page
A service from the Financial Times